论文部分内容阅读
目的观察玉屏风颗粒和匹多莫德对反复呼吸道感染患儿的临床疗效及对体液免疫水平的影响。方法 100例反复呼吸道感染患儿随机分为对照组和试验组,每组50例。对照组口服匹多莫德0.4 g,每天2次,2周后每次口服匹多莫德0.4 g,每天1次;试验组每天冲服玉屏风颗粒,1~3岁患儿5 g,4~6岁患儿7.5 g,7~9岁患儿10 g,10~14岁患儿15 g,分3次服用,2组均连续治疗3个月。比较2组患儿的临床疗效、免疫水平、肿瘤坏死因子-α(TNF-α)和白细胞介素-2(IL-2)水平。结果治疗后,试验组总有效率为96.00%(48/50例),对照组总有效率为84.00%(42/50例),差异有统计学意义(P<0.05)。治疗后,试验组免疫球蛋白A(Ig A)为(1.51±0.17)g·L~(-1),免疫球蛋白G(Ig G)为(11.94±2.32)g·L~(-1),免疫球蛋白M(Ig M)为(1.68±0.32)g·L~(-1);对照组Ig A为(1.01±0.21)g·L~(-1),Ig G为(8.08±2.07)g·L~(-1),Ig M为(1.29±0.38)g·L~(-1),与治疗前相比,差异有统计学意义(均P<0.01),试验组与对照组相比差异有统计学意义(均P<0.01)。试验组治疗后TNF-α为(0.32±0.19)ng·m L~(-1),IL-2为(16.46±9.34)ng·m L~(-1);对照组的TNF-α为(0.83±0.29)ng·m L~(-1),IL-2为(53.14±20.63)ng·m L~(-1)(P<0.05)。治疗中未出现恶心、呕吐、腹泻、皮疹等药物不良反应。结论反复呼吸道感染用玉屏风颗粒治疗能够改善患者体液免疫水平。
Objective To observe the clinical efficacy of Yupingfeng granule and Pidotimod on children with recurrent respiratory tract infections and their effects on humoral immunity. Methods 100 cases of children with recurrent respiratory tract infection were randomly divided into control group and experimental group, 50 cases in each group. The patients in the control group were given podolamide 0.4 g orally twice a day for 2 weeks and pindolol 0.4 g once daily for 2 weeks. The experimental group was treated with Yupingfeng granule once daily for 5 to 4 years, 7.5 g of children aged 6 years, 10 g of children aged 7 to 9 years, 15 g of children aged 10 to 14 were divided into 3 doses, 2 groups were treated for 3 months. The clinical efficacy, immunological level, tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2) levels were compared between the two groups. Results After treatment, the total effective rate was 96.00% (48/50) in the experimental group and 84.00% (42/50) in the control group, with a significant difference (P <0.05). After treatment, the immunoglobulin A (IgA) in the test group was (1.51 ± 0.17) g · L -1 and that of Ig G was (11.94 ± 2.32) g · L -1 , Ig M was (1.68 ± 0.32) g · L -1 in the control group, Ig A was (1.01 ± 0.21) g · L -1 in the control group, and Ig G was (8.08 ± 2.07) ) g · L -1 and Ig M was (1.29 ± 0.38) g · L -1, there were significant differences between before and after treatment (all P <0.01) Compared with the difference was statistically significant (all P <0.01). The level of TNF-α in the experimental group was (0.32 ± 0.19) ng · m L -1 and the level of IL-2 was (16.46 ± 9.34) ng · m L -1. The TNF-α in the control group was ( 0.83 ± 0.29 ng · m L -1, and IL-2 was (53.14 ± 20.63) ng · m L -1 (P <0.05). Nausea, vomiting, diarrhea, rash and other adverse drug reactions did not occur during treatment. Conclusion Respiratory tract infection with Yupingfeng particles can improve the level of humoral immunity in patients.